Morningstar

Incyte Corp INCY

Stock XNAS Rating as of Oct 2, 2026

News

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

Business Wire Sep 25, 2026, 11:00:00 PM
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio

Business Wire Sep 22, 2026, 12:30:00 PM
Incyte to Present at Upcoming Investor Conferences

Business Wire Sep 1, 2026, 12:00:00 PM
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire Aug 7, 2026, 8:30:00 PM
Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

Business Wire Jul 29, 2026, 10:00:00 AM
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates

Business Wire Jul 28, 2026, 11:00:00 AM
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

PR Newswire Jul 20, 2026, 12:00:00 PM
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers

Business Wire Jul 17, 2026, 5:10:00 PM
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

Business Wire Jul 13, 2026, 8:00:00 AM
Incyte to Report Second Quarter Financial Results

Business Wire Jul 8, 2026, 12:00:00 PM
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio

Business Wire Jul 6, 2026, 12:39:00 PM
Incyte Gets FDA Approval for Extended-Release Version of Jakafi Treatment

Global News Select May 1, 2026, 10:03:00 PM
Eli Lilly, Incyte Get CHMP Backing for Olumiant in Adolescents With Severe Alopecia Areata

Global News Select Feb 27, 2026, 2:38:00 PM
Incyte Gets FDA Approval for Dermatitis Cream for Young Children

Global News Select Sep 18, 2025, 8:51:00 PM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.